NCT04753216 2023-01-19Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerNorthwestern UniversityPhase 2 Completed3 enrolled 15 charts